PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33970096-0 2021 Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report. olaparib 81-89 phosphatase and tensin homolog Homo sapiens 31-35 25888415-11 2015 Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed functional Phosphatase and tensin homolog (PTEN). olaparib 21-29 phosphatase and tensin homolog Homo sapiens 148-152 33138032-8 2020 Cell proliferation studies were used to measure any potential added sensitivity of PTEN-null cells to the clinically-relevant PARPi, olaparib. olaparib 133-141 phosphatase and tensin homolog Homo sapiens 83-87 31714594-11 2020 Treatment with olaparib increased phosphorylation of ATM and PTEN while decreasing the phosphorylation of AKT and mTOR and inducing autophagy. olaparib 15-23 phosphatase and tensin homolog Homo sapiens 61-65 29500400-1 2018 Here we report that PTEN contributes to DNA double-strand break (DSB) repair via homologous recombination (HR), as evidenced by (i) inhibition of HR in a reporter plasmid assay, (ii) enhanced sensitivity to mitomycin-C or olaparib and (iii) reduced RAD51 loading at IR-induced DSBs upon PTEN knockdown. olaparib 222-230 phosphatase and tensin homolog Homo sapiens 20-24 28759753-0 2017 Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib. olaparib 74-82 phosphatase and tensin homolog Homo sapiens 66-70 28759753-5 2017 PTEN-deficient BT549 cells are sensitive to olaparib, which shows the synthetic lethality between PTEN and PARP1. olaparib 44-52 phosphatase and tensin homolog Homo sapiens 0-4 28759753-5 2017 PTEN-deficient BT549 cells are sensitive to olaparib, which shows the synthetic lethality between PTEN and PARP1. olaparib 44-52 phosphatase and tensin homolog Homo sapiens 98-102 28759753-6 2017 We expressed PTEN in BT549 cells and found PTEN-proficient BT549 cells resist to olaparib. olaparib 81-89 phosphatase and tensin homolog Homo sapiens 13-17 28759753-6 2017 We expressed PTEN in BT549 cells and found PTEN-proficient BT549 cells resist to olaparib. olaparib 81-89 phosphatase and tensin homolog Homo sapiens 43-47 28759753-10 2017 MTT assay showed 5muM RI-1 did not change the survival of PTEN-proficient BT549 cells, however, this dose of RI-1 sensitized PTEN-proficient BT549 cells to olaparib. olaparib 156-164 phosphatase and tensin homolog Homo sapiens 125-129 28759753-11 2017 Consequently, these results demonstrate that inhibition of Rad51 can sensitize BT549 cells with wild type PTEN to olaparib, which would contribute to using PARP inhibitors in individual treatment of breast cancer patients with PTEN variations. olaparib 114-122 phosphatase and tensin homolog Homo sapiens 227-231 25888415-15 2015 CONCLUSION: Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA. olaparib 170-178 phosphatase and tensin homolog Homo sapiens 63-67 23239809-8 2013 Ablation of PTEN in PC-9 cells increased sensitivity to olaparib and cisplatin. olaparib 56-64 phosphatase and tensin homolog Homo sapiens 12-16 24222661-9 2013 These two mechanisms may account for the sensitization of PTEN-null tumors to olaparib with estrogen deprivation. olaparib 78-86 phosphatase and tensin homolog Homo sapiens 58-62 24625059-4 2014 We examined the anti-tumor activity of olaparib, a PARP inhibitor, and its correlation between the sensitivity and status of PTEN in endometrial cancer cell lines. olaparib 39-47 phosphatase and tensin homolog Homo sapiens 125-129 24675890-6 2014 Furthermore, treatment of tumor cells with PARP1 inhibitor AZD2281 can compromise doxorubicin-induced PTEN suppression and enhance the inhibitory effect of doxorubicin. olaparib 59-66 phosphatase and tensin homolog Homo sapiens 102-106 20049732-2 2009 Following on a recent paper that demonstrates the clinical application of this strategy (Fong et al, 2009), Chris Lord and Alan Ashworth further explore the approach and show that poly(ADP-ribose) polymerase (PARP) inhibitors such as Olaparib can selectively target cancer cells defective in phosphatase and tensin homologue (PTEN, Mendes-Pereira et al, 2009) and that methotrexate is selectively lethal to MutS-homologue-2 (MSH2)-deficient tumour cells (Martin et al, 2009). olaparib 234-242 phosphatase and tensin homolog Homo sapiens 292-324 20049732-2 2009 Following on a recent paper that demonstrates the clinical application of this strategy (Fong et al, 2009), Chris Lord and Alan Ashworth further explore the approach and show that poly(ADP-ribose) polymerase (PARP) inhibitors such as Olaparib can selectively target cancer cells defective in phosphatase and tensin homologue (PTEN, Mendes-Pereira et al, 2009) and that methotrexate is selectively lethal to MutS-homologue-2 (MSH2)-deficient tumour cells (Martin et al, 2009). olaparib 234-242 phosphatase and tensin homolog Homo sapiens 326-330